抗PD-1/PD-L1和CTLA-4免疫治疗在头颈鳞癌中的研究进展

头颈鳞癌(Head and neck squamous cell carcinoma,HNSCC)患者被诊断时多为晚期,传统方案治疗后复发率约为60%、转移率约为30%。而复发/转移性头颈鳞癌(Recurrent/metastasis HNSCC,R/M HNSCC)患者的治疗手段有限,长期生存率有待提高。免疫检查点抑制剂的出现有效的提高了这些患者的总生存期,为HNSCC患者带来了希望。本文总结了近年来程序性死亡蛋白1(PD-1)、程序性死亡蛋白1配体(PD-L1)和细胞毒性T淋巴细胞相关抗原4(CTLA-4)抑制剂及其组合疗法在头颈鳞癌中的研究进展,希望为临床医师提供新的治疗方案。

Research progress of anti-PD-1/PD-L1 and anti-CTLA-4 immunotherapy in head and neck squamous cell carcinoma

Most patients with head and neck squamous cell carcinoma(HNSCC)are in advanced stage when they are diagnosed.The recurrence rate and metastasis rate of traditional regimen are about 60% and 30%,respectively.However,the treatment of recurrent and metastatic HNSCC(R/M HNSCC)is limited,and the long-term survival rate needs to be improved.The emergence of immune checkpoint inhibitors can effectively improve the overall survival of these patients,and bring hope for HNSCC patients.This paper summarizes the research progress of programmed death protein-1(PD-1),programmed death ligand-1(PD-L1)and cytotoxic T lymphocyte associated antigen 4(CTLA-4)inhibitors and their combination therapy in HNSCC in recent years,hoping to provide a new treatment for clinicians.